Proguanil and pyrimethamine are antifolate drugs with distinct chemical structures that are used commonly in the prophylaxis and treatment of Plasmodium falciparum malaria. Clinical reports and field studies have suggested that some parasites refractory to proguanil can be treated with pyrimethamine, and vice versa. Analysis of the P. falciparum dihydrofolate reductase (DbFR) from different parasites reveals the-structural basis for differential susceptibility to these antifolate drugs. Parasites harboring a pair of point mutations from Ala-16 to Val-16 and from Ser-108 to Thr-108 are resistant to cycloguanil (the active metabolite of proguanil) but not to pyrimethamine. A single Asn-108 mutation, on the other hand, confers resistance to pyrimethamine with only a moderate decrease in susceptibility to cycloguanil. Significant crossresistance to both drugs occurs in parasites having mutations that include Ser-108lOS Asn-108 and Ile-164 -Leu-164. These results reflect the distinct structures of pyrimethamine and cycloguanil and suggest fine differences in binding within the active site cavity of DHFR. Alternative inhibitors, used alone or in combination, may be effective against some strains of cycloguanil-or pyrimethamine-resistant malaria.
Proguanil and pyrimethamine, introduced nearly 40 years ago (1, 2) , were powerful additions to the spectrum ofantimalarial agents. Both drugs are specific inhibitors of the enzyme dihydrofolate reductase (DHFR; 5,6,7,8-tetrahydrofolate: NADP+ oxidoreductase, EC 1.5.1.3) and, in combination with sulfa drugs (Fig. 1) , have been distributed widely for use against malaria infections. Shortly after the release of each compound, however, prophylactic and therapeutic failures against Plasmodium falciparum were reported. Antifolate resistance has subsequently become a major problem in endemic regions throughout the world. The prevalence of resistant strains, and the risk of severe cutaneous reactions from combined administration with sulfa drugs, have limited the clinical utility of pyrimethamine and proguanil in prophylaxis of malaria (3) .
Several reports have noted that pyrimethamine and proguanil resistance in P. falciparum may occur independently. In Malaya in the early 1950s, where prophylactic use of proguanil was widespread, Wilson and Edeson found no consistent cross-resistance between proguanil and pyrimethamine (4) . More recent studies have reported proguanil provides effective protection in some regions where pyrimethamine resistance occurs (5, 6) . Since pyrimethamine resistance results from a point mutation to Asn-108 in the DHFR of P. falciparum (7) (8) (9) , the question arises whether proguanil resistance is conferred by different mutations in DHFR. In this report we examine point mutations in several P. falciparum clones and lines that exhibit different responses to pyrimethamine and cycloguanil (the active metabolite of proguanil). We show that parasites containing a pair of point mutations (Ser-108 --Thr-108 and Ala-16
Val-16) are resistant to cycloguanil but not to pyrimethamine. High levels of resistance to both cycloguanil and pyrimethamine are associated with the mutation Ile-164 -* Leu-164 in conjunction with Ser-108 --Asn-108.
MATERIALS AND METHODS
Parasite Cultivation. Parasites used in this work have been described: the clones HB3 (10), 3D7 (11), SL/D6 (12) , W2 (12), It.G2.F6 (13) , and It.D12 (13) ; and the lines FCR3 (14) , UPA (15, 16) , and FCB (17) . Clone V1/S was obtained from the mixed isolate V1 (18) after selection by pyrimethamine and cloning by limiting dilution (19) . Cultures were maintained in vitro by standard methods (20) . Drug Susceptibility Assays. Pyrimethamine and cycloguanil susceptibilities were performed both by microscopic determinations of parasitemia (7) and by [3H]hypoxanthine uptake (21) . Assays were conducted independently in two laboratories. Antagonism of drug effect by folic acid and p-aminobenzoic acid (PABA) was investigated by varying the concentrations of these compounds in the culture medium (22 In P. falciparum the DHFR domain is part of the bifunctional enzyme dihydrofolate reductase-thymidylate synthase (DHFR/TS). Oligonucleotide primers were designed from the gene sequence (23) and used in the polymerase chain reaction to amplify the DHFR domain as described (7) . Fifty nanograms of P. falciparum DNA (representing -1.5 X 106 copies of the genome) was used as the starting material. Both strands of amplified DNA were sequenced by a modification of the method reported by Innis et al. (24) . Two microliters of the polymerase chain reaction product were used in a Abbreviations: DHFR, dihydrofolate reductase; PABA, p-aminobenzoic acid.
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Structures
Common second reaction containing a single primer, promoting amplification of just one strand. After precipitation of the single-stranded template in isopropanol, nucleotide sequence data were obtained with sequencing primers SP1-SP6 (7) and the dideoxynucleotide method (Sequenase kit, United States Biochemical).
RESULTS AND DISCUSSION
Pyrimethamine and cycloguanil susceptibilities of 10 P. falciparum clones and lines were determined in vitro (Table 1) .
Because relative levels of susceptibility to pyrimethamine and cycloguanil vary with folate and PABA concentrations in the assay medium (22) , values were measured in both normal RPMI 1640 medium and folate/PABA-free RPMI 1640 medium. Clones SL/D6 (from a patient treated successfully with pyrimethamine alone) and W2 (from the multidrug-resistant isolate Indo-I1I) were included in the analysis, as these clones serve in the characterization of drug-resistant malaria strains (25) . In folate/PABA-free medium, patient isolates from pyrimethamine/sulfadoxine failures are known to exhibit The Asn-108 mutation in DHFR has already been shown to confer resistance to pyrimethamine (7-9). Table 1 confirms the presence of this mutation in all four pyrimethamineresistant clones. Only a decrease in cycloguanil susceptibility by a factor of 20 is apparent in the HB3 clone containing this mutation. Presence of an ancillary mutation Asn-51 -+ Ile-51 in the It.D12 clone is associated with an additional decrease by a factor of 5 in response to both drugs.
Using assay values obtained in normal RPMI 1640 medium, we previously found parasites containing three mutations (Asn-108, Ile-51, and Arg-59) to be 16-to 32-fold more pyrimethamine resistant than parasites containing the Asn-108 mutation alone (7) . However, Table 1 shows that the W2 parasite, which contains all three of these mutations, exhibits different relative levels of resistance depending upon the PABA and folate concentrations in the culture medium. Assays of the W2 clone in folate/PABA-free RPMI 1640 medium yielded markedly lower IC50 values than did assays performed in standard RPMI 1640 medium (1 ,ug of folate and 1 ,ug of PABA per ml). Antagonistic effects of exogenous PABA and folate on the activity of antifolate drugs have been described (22) the SL/D6 response ( Fig. 2A) . Folate produced a similar, although less pronounced, effect (Fig. 2B ). We note that serum level ranges of PABA and folate in vivo are =0.5-1 ng/ml and 5-20 ng/ml, respectively (27, 28 tA -previous paper demonstrated linkage of the Asn-108 point mutation to pyrimethamine resistance in the 3D7 x HB3 cross (7) . Analysis of a second cross (involving a clone derived from W2) has shown further that high levels of resistance at elevated PABA and folate concentrations are linked to the Ile-51 and Arg-59 mutations in the DHFR locus (unpublished results). A second argument that drug resistance is from alterations in the DHFR domain is provided from the data in Table 1 . This table lists the mutations of 10 independent parasite lines from geographically distant regions. Of the 9 that do not contain the Leu-164 mutation, 4 are cycloguanil resistant and 5 are cycloguanil susceptible in the absence of folate and PABA antagonism. Because of the innumerable crossover events separating these strains, the chance of a random correlation between the Thr-108/Val-16 mutations and cycloguanil resistance is minimal (on the order of 0.59 -0.2%). Finally, a third argument derives from alignment of the mutations with known structures from other organisms (7, 23, 29) . All mutations align with residues known to occur at the active site cavity of DHFR. Since pyrimethamine and cycloguanil bind in this cavity, the mutations occur where they would be expected. Given the linkage data already obtained from the crosses and numerous independent isolates, the conclusion that the point mutations are responsible for resistance in natural strains of P. falciparum is compelling.
The various mutations in the DHFR enzyme appear to have arisen in response to the different ways cycloguanil and pyrimethamine bind to DHFR. Alignment of the P. falciparum sequence with DHFR sequences from other organisms shows that all of these mutations occur in conserved regions that border the active site cavity of the enzyme (Fig.  3) . Residue 108 occurs in the C a-helix of the enzyme; residues 51 and 59 align in or near the B a-helix at the back of the cavity; and residues 16 and 164 are located in the A p-strand and E 8-strand, respectively. Residues at or near these positions have been shown to be involved in the binding of various inhibitors to avian, bacterial, and mammalian DHFRs (31) (32) (33) (34) .
It is interesting that Ser-108 -* Thr-108 and Ala-16
Val-16 occur together in cycloguanil-resistant pyrimethamine-susceptible parasites. With the exception of Plasmodium, Thr-108 has been reported at the analogous position of the C a-helix for all organisms studied to date (35) . Ser-108, however, is apparently the wild-type residue in P. falciparum. The role of Thr-108 and its relation to Val-16 need to be clarified by the ability to study these mutations independently, perhaps by means of stable transfection or heterologous expression.
The results of this work support clinical observations that alternative anti-DHFR agents can be effective against some strains ofpyrimethamine-or cycloguanil-resistant malaria. In addition to cycloguanil and pyrimethamine, known inhibitors of DHFR include other biguanil derivatives, triazines, and quinazoline analogs. Point mutations affecting one inhibitor might be countered in some cases by alternative antifolate drugs capable of acting against the mutant enzyme. However, it is already clear that multiply-resistant malaria strains are likely to spread with exposure to different antifolate drugs. Future chemotherapy with antifolate drugs will require knowledge of the distribution of resistant strains and discovery of new inhibitors that are effective against them.
Independent but concurrent work by Foote et al. (36) , using different lines of P. falciparum, has shown comparable linkage of the DHFR point mutations to cycloguanil and pyrimethamine resistance.
